LEFKOFSKY ERIC P sold $19.4M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 250,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $77.47 ($76.57–$78.86, $19.37M total) across 16 trades on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Sep 24, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The CEO's sizable sell may influence short‑term price action and investor sentiment.

02

Market read

Insider sell is a primary disclosure with moderate materiality, offering limited but actionable insight for traders.

03

What to watch

Potential upcoming financing round or strategic partnership that prompted the insider to free up cash.

Relevance 6/10Novelty 7/10Timing: post-market 2026-09-22

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Eric Lefkofsky sold 250,000 shares for $19.4M, reducing his stake to 100,000 shares via a 10b5-1 plan.

Expected impact

Potential short-term downside pressure, 2-4% decline over the next few days.

Evidence & confidence

Insider sales of this magnitude from a founder/CEO often precede negative sentiment, especially when holdings drop by 60%.

Market effects

May weigh on AI and health‑tech sector sentiment as investors watch founder activity.

Limited to US markets; no broader regional effect.

Minimal global impact beyond Tempus AI shareholders.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals; the stock may remain stable.

Key entities

  • Tempus AI, Inc.

    AI-driven healthcare data platform listed on Nasdaq under ticker TEM.

  • Eric Lefkofsky

    CEO and Chairman of Tempus AI, 10% owner.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.